Genenta Science (GNTA) CMO Russo resigns; Galimi steps in as acting CMO
Rhea-AI Filing Summary
Genenta Science S.p.A. reports a leadership change in its medical and development functions. On September 30, 2025, Carlo Russo, MD, resigned as Chief Medical Officer and Head of Development, effective immediately, after the Company waived any notice period required under his employment agreement. The Company states that his resignation was for personal reasons and did not arise from any disagreement with the Company.
On the same date, Dr. Francesco Galimi, age 58, was appointed acting Chief Medical Officer and Head of Development, effective immediately. He has served on Genenta’s Board of Directors since April 2025 and brings over 30 years of healthcare R&D experience, including senior roles at Adicet Bio, Amgen, Onyx Pharmaceuticals, and GNF/Novartis. Dr. Galimi holds an M.D. with a specialty in Medical Oncology and a Ph.D. in Oncology from the University of Torino Medical School and completed post-doctoral research at the Salk Institute.
Positive
- None.
Negative
- None.
Insights
Genenta replaces its CMO swiftly, naming an experienced board member as acting CMO.
The company discloses that Carlo Russo, MD, resigned as Chief Medical Officer and Head of Development effective September 30, 2025, with any contractual notice period waived. It specifies that his departure is for personal reasons and not due to a disagreement, which aims to reassure stakeholders that there is no reported strategic or scientific dispute driving the change.
On the same date, Genenta appointed board member Dr. Francesco Galimi as acting Chief Medical Officer and Head of Development. His background includes senior R&D and clinical leadership roles at Adicet Bio, Amgen, Onyx Pharmaceuticals, and GNF/Novartis, as well as oncology-focused medical and doctoral training and post-doctoral work on gene transfer models at the Salk Institute. The continuity provided by an internal director with deep oncology and development experience may help stabilize ongoing programs, though longer-term leadership structure will likely depend on future corporate decisions.
